Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments
- PMID: 33606962
- DOI: 10.1146/annurev-pharmtox-121120-012309
Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments
Abstract
In December 2019, a novel coronavirus crossed species barriers to infect humans and was effectively transmitted from person to person, leading to a worldwide pandemic. Development of effective clinical interventions, including vaccines and antiviral drugs that could prevent or limit theburden or transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global health priority. It is thus of utmost importance to assess possible therapeutic strategies against SARS-CoV-2 using experimental models that recapitulate aspects of the human disease. Here, we review available models currently being developed and used to study SARS-CoV-2 infection and highlight their application to screen potential therapeutic approaches, including repurposed antiviral drugs and vaccines. Each identified model provides a valuable insight into SARS-CoV-2 cellular tropism, replication kinetics, and cell damage that could ultimately enhance understanding of SARS-CoV-2 pathogenesis and protective immunity.
Keywords: COVID-19; SARS-CoV-2; animal models; in vitro models.
Similar articles
-
Cell and Animal Models for SARS-CoV-2 Research.Viruses. 2022 Jul 9;14(7):1507. doi: 10.3390/v14071507. Viruses. 2022. PMID: 35891487 Free PMC article. Review.
-
Pathogenesis-directed therapy of 2019 novel coronavirus disease.J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10. J Med Virol. 2021. PMID: 33073355 Review.
-
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.In Vivo. 2020 Jun;34(3 Suppl):1597-1602. doi: 10.21873/invivo.11949. In Vivo. 2020. PMID: 32503817 Free PMC article. Review.
-
An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.J Basic Clin Physiol Pharmacol. 2020 Sep 14;31(6). doi: 10.1515/jbcpp-2020-0113. J Basic Clin Physiol Pharmacol. 2020. PMID: 32924964
-
Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.Int J Infect Dis. 2021 Mar;104:441-451. doi: 10.1016/j.ijid.2021.01.035. Epub 2021 Jan 18. Int J Infect Dis. 2021. PMID: 33476760 Free PMC article. Review.
Cited by
-
A virus preservation solution that inactivates the virus while maintaining the virus particle intact.Ann Transl Med. 2022 Oct;10(19):1064. doi: 10.21037/atm-22-4295. Ann Transl Med. 2022. PMID: 36330392 Free PMC article.
-
Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone.Comput Biol Med. 2022 Sep;148:105814. doi: 10.1016/j.compbiomed.2022.105814. Epub 2022 Jul 11. Comput Biol Med. 2022. PMID: 35841781 Free PMC article.
-
Transient global amnesia after COVID-19: A systematic scoping review of case reports.Curr J Neurol. 2022 Oct 7;21(4):244-250. doi: 10.18502/cjn.v21i4.11722. Curr J Neurol. 2022. PMID: 38011367 Free PMC article.
-
The interactions of SARS-CoV-2 with cocirculating pathogens: Epidemiological implications and current knowledge gaps.PLoS Pathog. 2023 Mar 8;19(3):e1011167. doi: 10.1371/journal.ppat.1011167. eCollection 2023 Mar. PLoS Pathog. 2023. PMID: 36888684 Free PMC article. Review.
-
Protecting Human and Animal Health: The Road from Animal Models to New Approach Methods.Pharmacol Rev. 2024 Feb 13;76(2):251-266. doi: 10.1124/pharmrev.123.000967. Pharmacol Rev. 2024. PMID: 38351072 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous